机译:通过抑制SRC,Verapamil和Dasatinib通过增加BIM的表达和MDR1和Survivin的表达增加,克服多药抗性,并且在人类多药中的骨髓瘤细胞中的表达
Division of Pharmacotherapy Kinki University School of Pharmacy Kowakae Higashi-Osaka Japan;
Division of Pharmacotherapy Kinki University School of Pharmacy Kowakae Higashi-Osaka Japan;
Department of Pathology Kinki University School of Medicine Osakasayama Osaka Japan;
Department of Surgery Kinki University School of Medicine Osakasayama Osaka Japan;
Division of Pharmacotherapy Kinki University School of Pharmacy Kowakae Higashi-Osaka Japan;
Division of Pharmacotherapy Kinki University School of Pharmacy Kowakae Higashi-Osaka Japan;
Division of Pharmacotherapy Kinki University School of Pharmacy Kowakae Higashi-Osaka Japan;
Division of Pharmacotherapy Kinki University School of Pharmacy Kowakae Higashi-Osaka Japan;
Division of Pharmacotherapy Kinki University School of Pharmacy Kowakae Higashi-Osaka Japan;
Division of Pharmacotherapy Kinki University School of Pharmacy Kowakae Higashi-Osaka Japan;
Department of Pharmacy Izumi Municipal Hospital Izumi Osaka Japan;
Department of Pharmacy Japanese Red Cross Society Wakayama Medical Center Wakayama Japan;
Department of Pathology Kinki University School of Medicine Osakasayama Osaka Japan;
Division of Pharmacotherapy Kinki University School of Pharmacy Kowakae Higashi-Osaka Japan;
Bim; Dasatinib; Drug resistance; MDR1; Multiple myeloma; Src; Survivin; Verapamil;
机译:通过抑制Src,维拉帕米和达沙替尼通过在人多药耐药性骨髓瘤细胞中增加Bim表达并降低MDR1和survivin的表达,从而克服了多药耐药性
机译:通过抑制SRC,Verapamil和Dasatinib通过增加BIM的表达和MDR1和Survivin的表达增加,克服多药抗性,并且在人类多药中的骨髓瘤细胞中的表达
机译:MDR1和survivin的过度表达以及Bim表达的降低介导了多发性骨髓瘤细胞的多药耐药性
机译:抑制survivin表达可增加人类肝癌的放射敏感性HepG2细胞转化为高LET碳离子
机译:靶向微管蛋白的血清序列结合位点以克服选择性Survivin抑制剂的多药耐药性和抗癌疗效
机译:多药耐药性相关蛋白(MRP)MDR1和DNA拓扑异构酶II在人多药耐药性膀胱癌细胞系中的表达。
机译:多药耐药性相关蛋白(MRP),MDR1和DNA拓扑异构酶II在人多药耐药性膀胱癌细胞系中的表达。